Cargando…

Incretin Effects on β-Cell Function, Replication, and Mass: The human perspective

Detalles Bibliográficos
Autor principal:	Garber, Alan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Diabetes Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632189/ https://www.ncbi.nlm.nih.gov/pubmed/21525465 http://dx.doi.org/10.2337/dc11-s230

Ejemplares similares

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
por: Garber, Alan J.
Publicado: (2011)

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
por: Meier, Juris J., et al.
Publicado: (2010)

Combined Pharmacologic/Nonpharmacologic Intervention in Individuals at High Risk of Developing Type 2 Diabetes: Pro pharmacologic therapy
por: Garber, Alan J.
Publicado: (2009)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Long-Term Benefits From Lifestyle Interventions for Type 2 Diabetes Prevention: Time to expand the efforts
por: Tuomilehto, Jaakko, et al.
Publicado: (2011)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
por: Lebovitz, Harold E.
Publicado: (2011)

Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
por: Miccoli, Roberto, et al.
Publicado: (2011)

Glucokinase Activators for Diabetes Therapy: May 2010 status report
por: Matschinsky, Franz M., et al.
Publicado: (2011)

Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes
por: Handelsman, Yehuda
Publicado: (2011)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

An Outline of the Allen Method
Publicado: (1919)

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
por: Chon, Suk, et al.
Publicado: (2016)

Effects of Incretin Pathway Elements on Bone Properties
por: Abdi, Arezoo M, et al.
Publicado: (2023)

Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
por: Drucker, Daniel J.
Publicado: (2013)

β-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults
por: Cernea, Simona, et al.
Publicado: (2009)

Goals of Treatment for Type 2 Diabetes: β-Cell preservation for glycemic control
por: Marchetti, Piero, et al.
Publicado: (2009)

Navigating the Alcohol Treatment Pathway: A Qualitative Study from the Service Users' Perspective
por: Gilburt, Helen, et al.
Publicado: (2015)

Role of Reduced β-Cell Mass Versus Impaired β-Cell Function in the Pathogenesis of Type 2 Diabetes
por: Meier, Juris J., et al.
Publicado: (2013)

Historical Perspective: Beginnings of the β-Cell: Current Perspectives in β-Cell Development
por: Seymour, Philip A., et al.
Publicado: (2011)

β-Cell Growth and Regeneration: Replication Is Only Part of the Story
por: Bonner-Weir, Susan, et al.
Publicado: (2010)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
por: Cohen-Solal, Alain, et al.
Publicado: (2009)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
por: Winthrop, Kevin, et al.
Publicado: (2022)

Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial
por: Siminiak, Tomasz, et al.
Publicado: (2012)

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
por: Briot, Karine, et al.
Publicado: (2021)

Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy
por: Ellimuttil, Tracey M, et al.
Publicado: (2021)

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
por: Smits, Mark M, et al.
Publicado: (2015)

PSUN326 An Interim Analysis of Healthcare Professionals’ Gaps in Incretin Knowledge Before and After Education
por: Brechtelsbauer, Erika L, et al.
Publicado: (2022)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation
por: Nyirenda, Mukanthu H, et al.
Publicado: (2023)

A double‐blind, placebo‐controlled trial on the antihypertensive treatment effect of a quadruple single‐pill combination
por: Hu, Lei‐Xiao, et al.
Publicado: (2021)

The effectiveness of an attention‐based intervention for school‐aged autistic children with anger regulating problems: A randomized controlled trial
por: Clifford, Pamela, et al.
Publicado: (2022)

Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies
por: Reinisch, Walter, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sa435mj9el62e1s452efc0rav8